Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 70.12%.

  • Century Therapeutics' EBITDA Margin rose 33930400.0% to 70.12% in Q1 2025 from the same period last year, while for Sep 2025 it was 23.97%, marking a year-over-year increase of 47368800.0%. This contributed to the annual value of 1917.59% for FY2024, which is 40825400.0% up from last year.
  • As of Q1 2025, Century Therapeutics' EBITDA Margin stood at 70.12%, which was up 33930400.0% from 874.84% recorded in Q4 2024.
  • Century Therapeutics' 5-year EBITDA Margin high stood at 70.12% for Q1 2025, and its period low was 33558.59% during Q2 2023.
  • In the last 4 years, Century Therapeutics' EBITDA Margin had a median value of 3733.93% in 2022 and averaged 7454.87%.
  • Per our database at Business Quant, Century Therapeutics' EBITDA Margin crashed by -312820800bps in 2023 and then surged by 295021700bps in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' EBITDA Margin stood at 5861.8% in 2022, then tumbled by -142bps to 14173.13% in 2023, then soared by 94bps to 874.84% in 2024, then skyrocketed by 108bps to 70.12% in 2025.
  • Its EBITDA Margin stands at 70.12% for Q1 2025, versus 874.84% for Q4 2024 and 3812.77% for Q3 2024.